Chronic Hepatitis News

May is Hepatitis Awareness Month, an annual campaign to raise awareness for viral hepatitis and its impact in the U.S. — and a month-long opening to address the importance of vaccination and testing for viral hepatitis with your patients.

Larsucosteral was well-tolerated and improved short-term biomarkers of liver injury or disease in a subset of patients with moderate to severe alcohol-associated hepatitis, according to research in The American Journal of Gastroenterology.

Metabolic comorbidities heightened risk for adverse liver-related events among patients with chronic hepatitis B virus, with the highest risk found among patients with multiple comorbidities, according to research.

Although Black individuals with chronic hepatitis B were less likely to meet treatment criteria, researchers reported no significant differences in treatment initiation between racial groups, according to data in JAMA Network Open.

Hepatitis C virus among the U.S. obstetric population rose nearly 10-fold over 20 years, which might reflect an increase in screening or prevalence, according to researchers.

A call back system in Taiwan helped retrieve patients with chronic hepatitis C virus infection who were lost to follow-up and has the potential to boost micro-elimination efforts, according to research in BMC Gastroenterology.

SEATTLE — The ALLIANCE trial showed positive data on bictegravir/emtricitabine/tenofovir alafenamide treatment for HIV and hepatitis B coinfection while also providing data on treatment outcome predictors.

WASHINGTON — Active IV or prescription drug use did not affect attainment of sustained virologic response when treatment adherence for hepatitis C virus was already variable, according to a poster presented at The Liver Meeting.

Direct-acting antiviral treatment significantly lowered the risk for mortality and liver and non-liver outcomes in patients with chronic hepatitis C virus infection, regardless of disease stage, researchers reported.

Topline findings from the phase 3 D-LIVR trial showed that lonafarnib — boosted with ritonavir and in combination with peginterferon alfa — improved responses in patients with chronic hepatitis D virus, Eiger BioPharmaceuticals announced.